Skip to main content
. Author manuscript; available in PMC: 2019 Dec 4.
Published in final edited form as: Cancer. 2018 Oct 6;124(22):4322–4331. doi: 10.1002/cncr.31740

TABLE 3.

Cisplatin and Cetuximab Toxicity Outcomes: Cases With 1 Year of Prior Claims Data

Characteristic Overall CDDP CTX Carboplatin P





No. % No. % No. % No. % CTX vs CDDP Carboplatin
vs CDDP

Weight loss 182 44.50 70 41.92 79 45.66 33 47.83 .486 .405
Antiemetics 289 70.66 154 92.22 74 42.77 61 88.41 <.001 .350
ED visits 161 39.36 68 40.72 66 38.15 27 39.13 .628 .821
Hospital/ED visits with nausea/emesis/diarrhea 108 26.41 56 33.53 32 18.50 20 28.99 .002 .497
Hospital/ED visits with dehydration 147 35.94 75 44.91 50 28.90 22 31.88 .002 .064
Hospital/ED visits with malnutrition 131 32.03 45 26.95 59 34.10 27 39.13 .152 .064
Gastrostomy or feeding tube 255 62.35 107 64.07 104 60.12 44 63.77 .452 .965
Dysphagia 283 69.19 117 70.06 117 67.63 49 71.01 .629 .884
Aspiration pneumonia 47 11.49 14 8.38 22 12.72 11 15.94 .194 .086
Pneumonia NOS 79 19.32 23 13.77 37 21.39 19 27.54 .066 .012

Abbreviations: CDDP, cisplatin; CTX, cetuximab; ED, emergency department; NOS, not otherwise specified.

Acute renal failure rates are not reported because of the low number of events, but they were not significant between groups (P =.274 for CTX vs CDDP; P =.925 for carboplatin vs CDDP).